Lipocine Total Liabilities 2012-2025 | LPCN

Lipocine total liabilities from 2012 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Lipocine Total Liabilities 2012-2025 | LPCN

Lipocine total liabilities from 2012 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.
Related Stocks
Company NameMarket
Cap
Chugai Pharmaceutical (CHGCY)$77.5B
Zoetis (ZTS)$65.6B
Daiichi Sankyo, - (DSNKY)$46.1B
Takeda Pharmaceutical (TAK)$45.9B
BeOne Medicines - (ONC)$32B
Sandoz Group AG (SDZNY)$25.2B
Summit Therapeutics (SMMT)$19.6B
Merck (MKKGY)$16.6B
Shionogi (SGIOY)$14.4B
United Therapeutics (UTHR)$13.2B
Neurocrine Biosciences (NBIX)$13B
Orion OYJ (ORINY)$11B
IPSEN (IPSEY)$10.5B
Corcept Therapeutics (CORT)$7.4B
Madrigal Pharmaceuticals (MDGL)$7.3B
Stevanato Group S.p.A (STVN)$7.3B
Grifols, S.A (GRFS)$6.9B
Ionis Pharmaceuticals (IONS)$6.6B
Hikma Pharmaceuticals Plc (HKMPF)$6.2B
Ono Pharmaceutical (OPHLF)$5.2B
Soleno Therapeutics (SLNO)$4.4B
Procaps Group, S.A (PROCF)$3.2B
Hypermarcas (HYPMY)$3B
Crinetics Pharmaceuticals (CRNX)$2.9B
Catalyst Pharmaceuticals (CPRX)$2.6B
NewAmsterdam Pharma (NAMS)$2.5B
AMNEAL PHARMACEUTICALS, INC (AMRX)$2.5B
Centessa Pharmaceuticals (CNTA)$2.1B
Ocular Therapeutix (OCUL)$1.8B
BioCryst Pharmaceuticals (BCRX)$1.8B